**TITLE**: Perilipin-1 autoantibodies linked to idiopathic lipodystrophy in the setting of two distinct breaks in immune tolerance


Caleigh Mandel-Brehm*, PhD, Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco CA

Sara E. Vazquez*, AB, Diabetes Center, Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco CA

Chris Liverman, MD PhD, Department of Pathology, University of California San Francisco, San Francisco CA

Mickie Cheng, MD PhD, Diabetes Center, Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco CA

Zoe Quandt, MD, Department of Medicine, University of California San Francisco, San Francisco CA

Andrew F. Kung, BA, Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco CA

Brenda Miao, BA, Diabetes Center, Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco CA

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Emmanuel Disse, MD-PhD, Hospices Civils de Lyon, Lyon Sud Hospital, Endocrinology Diabetology and Nutrition Department, Pierre-Bénite, France. ImmuCare, Cancer Institute of Hospices Civils de Lyon (IC-HCL), Lyon, France.
Christine Cugnet-Anceau, MD-MSc, Hospices Civils de Lyon, Lyon Sud Hospital, Endocrinology Diabetology and Nutrition Department, Pierre-Bénite, France. ImmuCare, Cancer Institute of Hospices Civils de Lyon (IC-HCL), Lyon, France.
Stéphane Dalle, MD-PhD Hospices Civils de Lyon, Lyon Sud Hospital, Dermatology Department, Pierre-Bénite, France. ImmuCare, Cancer Institute of Hospices Civils de Lyon (IC-HCL), Lyon, France.
Elizaveta Orlova, MD PhD, Endocrinology Research Centre, Institute of Paediatric Endocrinology, Moscow, Russia
Elena Frolova, PhD, National Medical Research Center of Children's Health, Moscow, Russia
Bergithe E. Oftedal, PhD, University of Bergen, Bergen, Norway; Department of Medicine, Haukeland University Hospital, Bergen, Norway
Michail S. Lionakis, MD, Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy & Infectious Diseases, National Institutes of Health, Bethesda, Maryland
Eystein S. Husebye, MD, Department of Clinical Science and K.G. Jebsen Center for Autoimmune disorders, University of Bergen, Bergen, Norway; Department of Medicine, Haukeland University Hospital, Bergen, Norway
Joseph L. DeRisi#, PhD, Chan Zuckerberg Biohub, Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco CA
Mark S. Anderson#, Diabetes Center, Department of Medicine, University of California
San Francisco, San Francisco CA

*Authors contributed equally to this work

#Co-corresponding authors

Corresponding author information:
Name: Dr. Mark Anderson
Address: 513 Parnassus Avenue, Box 0540, San Francisco, CA 94143
Email: manderson@diabetes.ucsf.edu
Phone: 415-502-8052
ABSTRACT

Background: Acquired lipodystrophy is often characterized as an idiopathic subtype of lipodystrophy. Despite suspicion of an immune-mediated pathology, biomarkers such as autoantibodies are generally lacking.

Methods: Here, we used an unbiased proteome-wide screening approach to identify autoantibodies to the adipocyte specific lipid droplet protein Perilipin-1 in a murine model of Autoimmune Polyendocrine Syndrome 1 (APS1). We then tested for PLIN1 autoantibodies in human subjects with lipodystrophy with two independent severe breaks in immune tolerance (including APS1) along with controls using a specific Radioligand Binding Assay and indirect immunofluorescence on fat tissue.

Results: We identified autoantibodies to the lipid-droplet protein Perilipin-1 (PLIN1) in two human case reports including the first reported case of human APS1 with acquired lipodystrophy. Further, we extend PLIN1 autoantibodies to a second non-APS1 patient who acquired lipodystrophy as an immune-related adverse event following cancer immunotherapy.

Conclusion: These data suggest that PLIN1 autoantibodies may represent a unifying marker of autoimmune lipodystrophy.
INTRODUCTION

Lipodystrophy is a clinical syndrome defined by progressive loss of adipose tissue in some parts of the body (partial) or throughout (generalized), and may be inherited (genetic/familial) or acquired.\(^1\) The excessive loss of adipocytes can lead to clinically severe outcomes including insulin resistance from lipolysis, metabolic abnormalities (diabetes mellitus and dyslipidemia) or even death.\(^1\)\(^-\)\(^3\) Lipodystrophy is diagnosed largely by clinical phenotype but heterogeneous presentation, clinical mimicry and frequent association with complex disorders necessitates biomarkers. Mutations in several lipid-droplet associated genes explain a genetic etiology for a subset of lipodystrophies; however, the acquired lipodystrophy subtype is largely idiopathic and biomarkers are lacking.\(^2\)\(^-\)\(^3\)

Frequent co-occurrence of acquired lipodystrophy with autoimmune disease has fueled suspicion of immune-mediated pathology.\(^4\)\(^-\)\(^6\) We hypothesized that autoimmune associated acquired lipodystrophy may be associated with a common autoantibody that is adipocyte-specific. Here, we identify autoantibodies to Perilipin-1 (PLIN1), a gene mutated in a subset of inherited lipodystrophies, in two clinical cases of autoimmune associated acquired lipodystrophy. One patient had a mutation in the Autoimmune Regulator gene, \textit{AIRE}.\(^7\) Mutations in \textit{AIRE} lead to the development of Autoimmune Polyglandular Syndrome type 1 (APS1/APECED; OMIM #240300), which is characterized by breakdown in central tolerance and production of high affinity antibodies to tissue-restricted antigens.\(^8\)\(^-\)\(^9\) The second patient developed lipodystrophy as an immune-related adverse event (irAE) following cancer immunotherapy.\(^10\) The disparate nature of these cases, bound by a common autoantibody and clinical
phenotype, suggests anti-PLIN1 may be a molecular indicator of autoimmune-associated acquired lipodystrophy in multiple clinical contexts.

METHODS

Human consents

Figure 2 involves our index APS1 patient with lipodystrophy (Case report 1) as well as APS1 patients without lipodystrophy and Healthy controls. Ethical approval for the study of the index APS1 patient with lipodystrophy was granted by the ethics committee at Endocrinology Research Center of Russia and all patients or their parents or guardians provided written informed consent. Ethical approval for the study of APS1 patients without lipodystrophy in Figure 2 was published previously\textsuperscript{11} and granted by the National Institute of Allergy and Infectious diseases (NIAID) Insititutional Review Board and patients provided written informed consent. Healthy control plasma for Figure 2 was obtained from the New York Blood Center, where they were collected under informed consent, including usage for research and publication. Figure 3 involves our index cancer immunotherapy patient with lipodystrophy (Case report 2) as well as checkpoint immunotherapy patient (CP) controls. Ethical approval, signed and written informed consent for case report 2 in Figure 3 was granted by Hospices Civils de Lyon under the study “Immune modulation Study in Patients with Metastatic Melanoma Treated with anti-PD1 Monoclonal Antibodies (PAIR)” (Clinicaltrials.gov NCT02626065). Ethical approval for the study of CP controls for Figure 3 was provided by the Human Research Protection Program International Review Board and all participants gave written informed consent. Supplemental Figure S2 contains study of additional APS1 patients
without lipodystrophy and Healthy Controls. Ethical approval for the study of all patients in Supplemental Figure 2 was granted by the Regional Ethical Committee of Western Norway (approval numbers 2009/2555 and 2018/1417), and all participants gave written informed consent for participation.

**Mouse sera collection.** Aire-/- mice were maintained on a Balb/C background under SPF barrier conditions at UCSF (IACUC approval AN177913). Sera from wild type and Aire-/- mice were prepared from tail vein bleeds (100ul) as described previously. Sera were flash frozen and stored at -80°C until use. Tissue for immunohistochemistry was prepared from adult wild type C57/B6 mice (Jackson Laboratory).

**Phage-Display and Immunoprecipitation (PhIP-Seq).** The T7 Phage Display library (PhIP-Seq library) employed here and experimental protocol were validated previously. Briefly, one microliter of mouse sera is incubated with one ml of PhIP-Seq library (10^10 pfu/mL) and incubated for 12-18 hours at 4°C. Antibody-bound phage are immunoprecipitated using a mix of protein A and protein G magnetic beads (Thermo), eluted and sequenced to identify the unknown phage antigen(s). Peptide counts were summed with respect to annotated proteins and total reads were normalized to 100,000 (RP100K). Candidate antigens were called based on read count > 50 RP100K in all Aire-/- mice and absent in Aire+/+ controls.

**Immunoprecipitation from 293T overexpression lysates.** Full-length mouse pCMV6-Plin1-myc-flag (Origene, RC206292) was sequenced verified and used for transfection in 293T cells. Whole cell lysates containing overexpressed PLIN1 were made to one
mg/ml and ten microliters was set for input for western blotting. One microliter of mouse sera or mock was added to 500 microliters of whole cell lysate, incubated for 12 hour at 4 degree. Antibodies were immunoprecipitated with protein A and protein G beads, washed three times with RIPA buffer (140 mM NaCl, 10 mM Tris-HCL, 1.0% Triton-X, 0.1% SDS) and boiled in 2X Laemmli with beta-mercaptoethanol. IP elutions were ran on a reducing SDS-PAGE 4-12% Bis-Tris gel (Thermo Fisher, NP0349BOX), transferred to nitrocellulose and immunoblotted with primary anti-Flag antibody (Rabbit anti-Flag, 1:5000, Cell Signaling Technology). To visualize anti-Flag we used infrared (IR) anti-rabbit secondary antibody (LICOR, 926-68703).

**Indirect immunofluorescence on mouse tissue.** Adult wild-type mice were sacrificed, then perfused with 4% Paraformaldehyde and stomach was post fixed for 1 hour, following sucrose/OCT embedding for cryosectioning. Sections were cut 12uM thick. Indirect immunofluorescent stains were obtained by incubating serum from anti-PLIN1 autoantibody positive sample or control sample or commercial antibody to PLIN1 (Sigma) at a dilution of 1:1000 on tissue section. Samples were washed and then developed with a FITC-conjugated secondary anti-human IgG antibody (Abcam). Representative images were captured on Nikon Ti confocal microscope at UCSF imaging core.

**Radioligand binding assay (RLBA).** An expression plasmid containing full-length human PLIN1 coding sequence under the control of a T7 promoter (Origene, RC206292) was sequence verified and used as a DNA template for *in vitro* translation of the PLIN1
protein. PLIN1 was synthesized in the presence of S35-Methionine to radiolabel the protein as previously described.\textsuperscript{15} Individual serum samples from both index patient cases, as well as a cohort of controls without evidence of lipodystrophy (including normal control patients, patients with identified APS1, and checkpoint blockade treated patients) were incubated with radiolabeled PLIN1 at 4C overnight. Antibody-bound protein was immunoprecipitated with protein A/G beads, washed, and total radioactive counts were obtained by scintillation. A commercial PLIN1-specific antibody (Sigma-Aldrich, # HPA024299) was used as a positive control. The Antibody index was calculated as follows: (sample value – mean blank value) / (positive control antibody value – mean blank value). A threshold for a positive result was set as three standard deviations above the mean for normal controls (indicated by dotted line).

RESULTS

Identification of anti-PLIN1 antibodies in the murine model of APS1.

Sera from a small subset of $\textit{Aire}^{-/-}$ mice ($n = 4$) were archived previously due to evidence of an autoantibody to an approximately 60 kDa antigen present in fat (data not shown). To identify the specificity of this autoantibody we tested sera from these four $\textit{Aire}^{-/-}$ mice as well as three age-matched wildtype controls ($\textit{Aire}^{+/+}$) by PhIP-Seq, a proteome-wide screening approach for autoantibody discovery.\textsuperscript{16} Although each sample exhibited a distinct pattern of PhIP-Seq reactivity, phage-displayed peptides derived from the PLIN1 gene were the only shared targets enriched by all four $\textit{Aire}^{-/-}$ mice and absent from all wild-type controls (Figure 1A). We validated antibody reactivity in $\textit{Aire}^{-/-}$ mice in two orthogonal assays. First, we demonstrate immunoprecipitation of recombinantly expressed mouse full-length Plin1-myc-flag from cell lysates using $\textit{Aire}^{-/-}$...
sera (Figure 1B). Second, we show co-localization of Aire-/- sera with commercial antibody to PLIN1 in mouse enteric fat tissue (Figure 1C). We also linked this finding to the activity of Aire in the thymus where we found the relative amounts of Plin1 RNA in medullary thymic epithelial cells (mTECs) to be dependent on proper Aire expression.\(^\text{17}\) (Supplemental Figure 1). The reduction in Plin1 expression was consistent with reductions of other known Aire-activated target genes, including Ins2, Cyp11a1, and Nlrp5, suggesting a possible mechanism contributing to autoimmunity to Plin1. These data in mice, together with prior reports linking PLIN1 mutations to inherited lipodystrophy subtypes, suggest that anti-PLIN1 immune response may also be present in human lipodystrophy associated either with APS1 or with alternative autoimmune-associated acquired lipodystrophies.\(^\text{18-19}\)

**Case report #1- APS1 Patient.** The first case of lipodystrophy in a patient with APS1 was recently reported.\(^{\text{7}}\) Briefly, by five years of age, the patient developed recurrent stomatitis, autoimmune hepatitis (Child Pugh Class C) and progressive lipodystrophy. Clinical testing for lipodystrophy associated genetic variants was negative (ZMPSTE24, LMNA, BSCL2, PLIN1, PTRF, LMNB2, POLD1, AKT2, CIDEC, PIK3CA, PPARG, PSMB8, CAV1, PPP1R3A, AGPAT2). Also by five years of age, candidiasis in the oral cavity and esophagus was diagnosed followed by primary adrenal insufficiency. At that point the diagnosis APS1 was made, confirmed by homozygocity for the most common AIRE mutation, R257X. He died of viral H1N1 pneumonia with respiratory and adrenal failures shortly after five years of age. Serum from the patient for autoantibody testing was obtained following onset of all symptoms listed, prior to death.
Testing for autoantibodies to PLIN1 in patient 1. A Radioactive Ligand Binding Assay (RLBA) was adapted for anti-PLIN1 autoantibody screening in humans. By this assay, autoantibodies to PLIN1 were present in Patient 1, but absent from a large cohort of APS1 patients without lipodystrophy (n=68) and healthy controls (n=54) (Figure 2A). PLIN1 autoreactivity in Patient 1 was further confirmed by immunohistochemistry utilizing mouse enteric tissue containing fat, which showed unambiguous colocalization of human sera and commercial antibody to PLIN1 (Figure 2B). Interestingly, using the same RLBA assay, PLIN1 autoantibodies were detected in several additional APS1 patients without lipodystrophy in an independent analysis involving a second, larger cohort of patients (Supplemental Figure 2). Absence of PLIN1 autoantibodies among healthy individuals was consistent across both independent analyses.

Case report #2: Checkpoint blockade-induced lipodystrophy. Rare instances of generalized lipodystrophy as an irAE following immune checkpoint inhibitor administration have recently been described. Patient 2 is a woman in her 60’s with metastatic melanoma detected in her brain, lung, and liver. The immune checkpoint inhibitor nivolumab (an anti-PD1 monoclonal antibody) was administered for 34 cycles over 16 months, at which time the patient presented with progressive weight loss and elevated liver function tests. Workup included a liver biopsy that revealed severe steatosis, and nivolumab treatment was halted due to concern for irAE. Over the next month, the patient developed further weight loss, hyperphagia, polydipsia, and polyuria. Type 1 diabetes–related autoantibodies (anti-GAD, IA2, and ZnT8) were negative and
fasting plasma insulin, C-peptide, HOMA of insulin resistance were all consistent with insulin resistant diabetes. Her physical exam was notable for severe loss of subcutaneous fat in a broad distribution with muscle prominence consistent with lipodystrophy. Laboratory testing was notable for an undetectable leptin level and elevated triglycerides. Clinical testing for 23 lipodystrophy associated genetic variants was also negative (AKT2, BSCL1, BSCL2, CAV1, CIDEC, DYRK1B, INSR, LIPE, LMF1, LMNA, LMNB2, NSMCE2, PCYT1A, PIK3R1, PLD3, PLIN1, POC1A, POLD1, PPARG, PSMB8, PTRF, TBC1D4, ZMPSTE24). A diagnosis of acquired generalized lipodystrophy was made and her diabetes was treated with metformin, dietary changes and high dose basal-bolus insulin. Four months following cessation of nivolumab, there was improvement in the patient’s diabetes as noted by decreased insulin requirements and partial improvement in hypertriglyceridemia. Serum samples for Patient 2 were collected at different time points throughout her clinical course under informed consent.

Longitudinal sera samples from Patient 2 were tested for autoantibodies to PLIN1 using RLBA. Patient #2 was negative for antibodies to PLIN1 prior to treatment with nivolumab, but was positive after 34 courses of nivolumab treatment, when she was noted to have weight loss and steatosis (Figure 3A). To validate the immunoreactivity, immuno-labeling of mouse enteric tissue with patient sera and commercial antibody to PLIN1 colocalized in samples corresponding to post-treatment and lipodystrophy diagnosis timepoints, but not pre-treatment samples (Figure 3B). Reactivity to PLIN1 appeared to decrease by 19 months after cessation of nivolumab, and although the
patient’s generalized lipodystrophy phenotype did not resolve their metabolic profile did improve.

**DISCUSSION**

Acquired lipodystrophy is an idiopathic clinical phenotype with a strong suspicion of autoimmune etiology\(^1\). Autoimmune disease can give rise to a wide variety of clinical phenotypes, which are often related to the expression patterns of the respective targeted protein autoantigens.\(^22\) Here, the study of these two patients, together with examination of mouse Aire-/- samples, suggests that acquired lipodystrophy may be marked by autoreactivity to the protein PLIN1. PLIN1 has restricted expression in adipocytes and has a well-established role in regulating lipid-droplet size and maintaining lipid homeostasis throughout the body.\(^23\) Furthermore, loss of *Plin1* expression in mice and humans leads to a lipodystrophy phenotype.\(^19,24\) Interestingly, a recent report using a candidate-based approach in humans identified PLIN1 as a putative autoantigen in three individual patients with autoimmune-associated acquired generalized lipodystrophy.\(^25\) Our unbiased, proteome-wide discovery of PLIN1 autoantibodies in an autoimmune-prone mouse model support these findings, and add to the growing evidence for anti-PLIN1 autoantibodies in a subset of patients with acquired lipodystrophy.

The two cases presented here are instructive in that they occurred in the setting of a breakdown in two key checkpoints on immune tolerance: 1) abnormal central tolerance mediated by *AIRE* mutations, and 2) inhibition of PD1 on peripheral T cells through exposure to immune checkpoint inhibitors.\(^7,10\) The co-occurrence of additional
immune responses in both patients, including autoimmune hepatitis and Addison’s
disease in the APS1 patient and an anti-cancer response in the nivolumab-treated
patient, provide strong circumstantial evidence that the lipodystrophy may also be of
autoimmune origin. Further bolstering this notion is the presence of T cell infiltrates in
the fat biopsy of the nivolumab-treated patient.10

Here we identify autoantibodies to PLIN1 in the first reported case of
lipodystrophy associated with APS1 in humans.7 In the setting of APS1, loss of immune
tolerance to peripheral organs is thought to occur through a loss of proper display of
tissue-specific antigens in the thymus. This loss in T cell tolerance is also associated
with the development of autoantibodies that reflect the T cell specificity.26 Interestingly,
in mining thymic gene expression data from mice lacking Aire expression, we found
evidence that Plin1 is expressed in the thymus in an Aire-dependent fashion
(Supplemental Figure 1) similar to other known self-antigens like Ins2 (insulin).17 These
results suggest individuals with a deficiency in AIRE may harbor a greater risk for the
development of lipodystrophy. Although lipodystrophy is rare in APS1, we suggest that
additional screening should be explored in this patient group, and conversely that
genetic testing for AIRE should be considered in young patients presenting with
unexplained lipodystrophy or metabolic abnormalities.

As in case report #2, we also identified PLIN1 antibodies in association with
acquired generalized lipodystrophy in the setting of cancer immunotherapy. As the
deployment of immune checkpoint blockade therapy across many types of cancers has
increased, so has the prevalence of associated irAEs.27 Endocrine adverse events can
appear suddenly in individual patients, and may manifest as common autoimmune
diseases such as hypothyroidism and type 1 diabetes, or rare autoimmune presentations such as hypophysitis, and more recently, acquired lipodystrophy.\textsuperscript{10,20-21}

Given the severe consequences of some irAE, developing new and improved markers for detecting those at risk is a clinical priority. Due to the fact that autoantibodies commonly precede detection of symptoms, autoantibodies to PLIN1 may provide a useful tool towards this goal.

Our data, together with prior associations of PLIN1 autoantibodies and acquired lipodystrophy warrant future studies to determine whether anti-PLIN1 antibody testing may be useful for identifying risk patients even prior to the onset of clinically apparent symptoms. Taken together, our results linking two distinct clinical settings of a break in immune tolerance to PLIN1 autoantibodies provides a new insight into the specificity of idiopathic lipodystrophy and provides to the growing evidence for PLIN1 antibodies as a biomarker for this syndrome.

\textbf{Acknowledgements:}

We thank New York Blood Center for donation of healthy plasmas for RLBA analysis.

\textbf{Funding:}

Z.Q. was supported by the American Diabetes Association grant 1-19-PDF-131. JDL is funded by a grant from Chan Zuckerberg Biohub. JDL and CMB are funded by the National Institute of Mental Health (NIMH) of the NIH (award 1R01MH122471-01). CMB is funded by The Emiko Terasaki Foundation (Project 7027742 / Fund B73335) and by the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (award 1K99NS117800-01). SEV is funded by the National Institute
of Diabetes and Digestive and Kidney Diseases of the NIH (award 1F30DK123915-01).

MSL is funded by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases (ZIA AI001175). MA is funded by the National Institute of Allergy and Infectious Diseases (5P01AI118688-04), the National Institute of General Medical Sciences (5T32GM007618-42). EH is funded by Stiftelsen Kristian Gerhard Jebsen, The Novo Nordisk Foundation, The Research Council of Norway and the Regional Health Authorities of Western Norway.

Conflicts of Interest:

SD received institutional research grants and travel cost covered by BMS and MSD.
REFERENCES


20. Camila Kruschewsky Falcao, Marina Campos Simoes Cabral, Jose Mauricio Mota, Samia Trigo Arbache, Aline Dantas Costa-Riquetto, David Queiroz Borges


Figures and Figure Legends:

**Figure 1.** Discovery and validation of autoantibodies to Perilipin-1 in *Aire-/-* mouse sera. (A) PhIP-Seq analysis in *Aire-/-* ("KO") and *Aire+/+* ("WT") mice. Aggregated Plin1 PhIP-Seq data from *Aire-/-* (KO, n=4) and *Aire+/+* (WT, n=3) mice. (B) Whole cell lysates generated from 293T cells expressing full-length mouse PLIN1 were incubated with sera from *Aire-/-* (KO, n=4) or *Aire+/+* (WT, n=3) mice. Antibodies were immunoprecipitated using AG beads and IP elutions were subject to SDS-PAGE.
immunoblotting. AG lane indicates an IP using AG beads only, no sera. Input lane indicates loading of whole cell lysate with and without (-) transfection of PLIN1-myc-flag plasmid. IP elutions and Input were immunostained with either anti-Flag IgG to identify positive anti-Plin1 signal, or anti-mouse IgG to show qualitative capture of IgG from sera. (C) Representative image of immunohistochemistry on mouse enteric tissue showing positive colocalization of antibodies from Aire-/- sera (KO) and commercial anti-Plin1 IgG. Primary antibodies from Aire-/- mouse (KO) sera and commercial antibody to PLIN1 were visualized with secondaries to Mouse IgG (Alexa-567, RED) and Rabbit IgG (Alexa-488, GREEN), respectively. DAPI (BLUE) stains nuclei.
Figure 2. Autoantibodies to PLIN1 in sera from a patient with APS1 and acquired lipodystrophy. (A) Radioligand binding assay for detection of anti-PLIN1 antibodies. Radiolabeled PLIN1 protein was incubated with sera from healthy controls (HC, n = 54) or from APS1 patients with or without lipodystrophy (APS1 +/- LD, n = 1/68). Dotted line indicates mean + 3SD of healthy controls. (B) Validation of autoantibodies to PLIN1 in orthogonal cell-based assay. Fixed stomach tissue of mice was mounted and immunostained with sera from Case report patient 1 and commercial antibody to PLIN1. A mix of secondary antibodies anti-Human IgG-alexa547 and anti-Rabbit alexa488 at 1:2000 were used to visualize Human IgG and PLIN1 antibodies, respectively. A Merge is provided on the right of individual images. Images taken at 20X magnification. Note yellow in Merge indicating colocalization of PLIN1 (Green) and Human IgG (RED). DAPI is blue and indicates nuclei. Scale bar indicates 100 microns.
Figure 3. Autoantibodies to PLIN1 in sera from a patient with autoimmune AGL following cancer immunotherapy. (A) Radioligand binding assays screening for PLIN1 antibodies in sera from all time points from index patient 2 as well as checkpoint-treated control patients without lipodystrophy (n=7), as done for case report 1. Dotted line indicates mean + 3 std. dev. of healthy controls (n = 11). Numbers to the right of circles indicate the time point series, for reference in panel B. The left panel describes the
clinical timeline corresponding to timepoints T0-T4. CPI was discontinued at 34 cycles (16 months) due to progressive weight loss and elevated LFTs, with further work-up over subsequent months. (B) Validation of autoantibodies to PLIN1 using immunohistochemistry on mouse enteric tissue, as done in Figure 2B. Sera was used from either a control (immunotherapy but no AGL) or case report 2 (Immunotherapy with AGL) with various time points. Each column represents an individual sample, from left to right; sera from checkpoint control pre-treatment, sera from checkpoint control post treatment with no autoimmunity, Case report 1 pre-therapy, Case report 1 post-therapy-1, Case report 1 post-therapy-3, Case report 1 post-therapy-4. Images are 600x600 pixel insets from original 40X image. Scale bar represents 100 microns. CP = Checkpoint patient controls.